Cleerly Secures $106M for AI-Driven Heart Disease Tool, Medicare Approval, and Expansion

Cleerly's AI technology is revolutionizing the way heart disease is detected and analyzed with its advanced coronary artery scanning tool. This innovative system creates a 3D model of coronary arteries using coronary computed tomography angiography (CCTA), allowing it to evaluate plaque, vessel narrowing, and potential blood flow issues with remarkable accuracy. Through extensive validation in multi-center trials, Cleerly's AI has been shown to surpass expert assessments in evaluating vessel conditions. Moreover, this technology significantly reduces the need for invasive testing by 86%, as evidenced by recent studies[1][2]. With FDA approval and a breakthrough designation for its disease staging approach, Cleerly's non-invasive evaluation of atherosclerotic plaque burden is critical for improving heart disease prevention, especially among seniors[2].